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ABSTRACT
Objective To examine the effects of fertility drugs on
overallriskofovariancancerusingdatafromalargecohort
of infertile women.
Design Population based cohort study.
Setting Danish hospitals and private fertility clinics.
Participants 54362 women with infertility problems
referred to all Danish fertility clinics during 1963-98. The
median age at first evaluation of infertility was 30 years
(range 16-55 years), and the median age at the end of
follow-up was 47 (range 18-81) years. Included in the
analysiswere156womenwithinvasiveepithelialovarian
cancer(cases)and1241subcohortmembersidentifiedin
the cohort during follow-up in 2006.
Main outcome measure Effect of four groups of fertility
drugs (gonadotrophins, clomifene citrate, human
chorionic gonadotrophin, and gonadotrophin releasing
hormone) on overall risk of ovarian cancer after
adjustment for potential confounding factors.
Results Analyses within cohort showed no overall
increased risk of ovarian cancer after any use of
gonadotrophins (rate ratio 0.83, 95% confidence interval
0.50 to 1.37), clomifene (1.14, 0.79 to 1.64), human
chorionic gonadotrophin (0.89, 0.62 to 1.29), or
gonadotrophin releasing hormone (0.80, 0.42 to 1.51).
Furthermore,noassociationswerefoundbetweenallfour
groups of fertility drugs and number of cycles of use,
length of follow-up, or parity.
ConclusionNoconvincingassociationwasfoundbetween
use of fertility drugs and risk of ovarian cancer.
INTRODUCTION
One of the best established risk factors for ovarian
cancer is parity, with nulliparous women having a
higher risk than parous women.
1-3 Furthermore, an
association may also exist between infertility, fertility
drugs, and risk of ovarian cancer. In view of the large,
constantly growing number of women requesting
fertility treatment and the high incidences of ovarian
cancer in most Western countries, the question of
whether fertility drugs increase the risk of ovarian
cancerhasreceivedmuchpublicattentionandresulted
in patient anxiety since the late 1970s.
Concern was intensified by the results of three
epidemiological studies,which showedincreased risks
of ovarian cancer among women treated with fertility
drugs,
4-6 particularly nulliparous women and those
who had used fertility drugs long term. Several
subsequent epidemiological studies were largely reas-
suringastheydidnotconfirmastronglinkbetweenuse
offertilitydrugsandriskofovariancancer.
7-21Manyof
these studies, however, had methodological limita-
tions: the cohort studies were of small size, had short
and incomplete follow-up, and did not control for
potentialconfounders,andthecase-controlstudieshad
problems with the validity of reported drug use.
22
Furthermore,moststudieswere notableto distinguish
the possible effects of fertility drugs from the under-
lying causes of infertility, which could independently
affect the risk of ovarian cancer.
4-1523-26
The two most recent studies, a case-cohort study
19
and a case-control study,
20 showed no overall increase
intheincidenceofovariancancerafteruseofclomifene
citrate or gonadotrophins. We established a cohort of
54362 Danish women who attended infertility clinics
during 1963-98. This potentially represents the largest
number of cases of ovarian cancer in any cohort of
women with infertility problems to date. We also
obtained extensive information about the women’s
drug histories and potential confounders. A previous
analysis
27 showed that the women in this cohort had a
46% higher risk of ovarian cancer than women in the
general Danish population after adjustment for parity,
which indicates that the increased risk might be
associated with infertility related factors other than
lower parity. We evaluated the effects of different
fertility drugs on the risk of ovarian cancer in this
cohort.
METHODS
The cohort has been described in detail in reports on
studies of the association between use of fertility drugs
and risks of breast cancer,
28 thyroid cancer,
29 and
malignant melanoma.
30 Briefly, the cohort comprised
women with infertility referred to all Danish hospitals
orprivateinfertilityclinicsduring1963-98.Inaddition
we included all women with a diagnosis of infertility
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recorded in the national patient registry, a nationwide
register of virtually all discharges for somatic condi-
tions from Danish hospitals since 1977. A total of
54449 women with primary or secondary infertility
were enrolled. All data were entered into a single
database, with one record for each woman, including
theinitialdatethatinfertilitywasevaluated,theclinic’s
name, and the woman’s civil registry number. To
verify the personal identification number and to
determine the date of migration or death, we linked
the cohort to the population based civil registration
system, with the civil registry number as the key
identifier.Ofthe54449infertilewomen,allbut87had
a valid civil registry number,leaving 54362 women in
the cohort for analysis.
Identification of cases
To determine the women’s status for ovarian cancer
after enrolment in the study, we used the civil registry
numbers to link the cohort to the Danish Cancer
Registry and the Danish Registry of Pathology. The
cancer registry contains nationwide information on all
incident cases of invasive cancer in Denmark since
1943, and the pathology registry contains information
on specimens from all Danish public and private
pathology departments and is updated daily. Because
the cancer registry was updated only until 31 Decem-
ber 2003 at the time of analysis we used the pathology
registertodetermineovariancancerstatusinthecohort
from 1 January 2004. We followed the cohort for
occurrence of ovarian cancer from the first date
infertility was evaluated until date of emigration, date
of death, or 30 June 2006, whichever occurred first.
Invasive ovarian cancer was diagnosed in 193 women
duringfollow-up.Forthepresentanalysisweexcluded
11 women with non-epithelial ovarian cancer and six
women with ovarian cancer of unspecific histological
type,leaving176womenwithepithelialovariancancer
in the study.
Identification of the subcohort
In the case-cohort design the experience of all cases is
comparedwiththatofarandomlyselectedsubcohort.
31
In the present study, we randomly selected 1360
women from the cohort in four strata according to age
at entry into the cohort (18-26, 27-30, 31-36, and
≥37 years) and five strata according to the year they
entered the cohort (1965-77, 1978-84, 1985-9, 1990-6,
and 1997-8).
Ascertainment of drug use and potential confounders
We collected hospital files and medical records on all
infertility related visits for all the women in whom
ovarian cancer developed and for members of the
subcohort. The records could not be found for 18
women,andthe causeofinfertilityfortwowomenwas
found to be sterilisation, leaving 156 women with
ovarian cancer (89%) for analysis. In the subcohort we
excluded 78 women because their hospital files could
not be found, eight because a diagnosis of infertility
could not be confirmed, and 33 because the cause of
infertility was previous sterilisation, leaving 1241
women in the subcohort (91%). Ovarian cancer was
diagnosed in eight women in the subcohort during the
follow-up period, and we therefore included these
womenbothascasesandasmembersofthe subcohort
in the analyses.
Informationwasabstractedonmedicalinterventions
for infertility, including fertility drugs prescribed and
the number of treatment cycles. For each treatment
cycleweabstractedthedatesofstartingandstoppingto
define the windows of exposure to the drugs. We also
intended to abstract information on the dosage of the
drugs,butthisinformationwasrecordedforonlyafew
women. From the medical records we abstracted
information about the causes of infertility and any use
of oral contraceptives, but this information was also
available for only a minority of the women. To obtain
informationonreproductivehistoryforalltheinfertile
women with ovarian cancer and for those in the
subcohort,welinkedthecohorttothecivilregistration
system and the Danish National Birth Registry by the
civil registry numbers. The population based national
birth registry contains information on all births in
Denmark since 1973. Thus we obtained information
on reproductive history from 1973 onwards from this
registerandreproductivehistorybefore1973fromthe
civil registration system, as this register allows linkage
between parents and children.
Table 1 |Rate ratios for ovarian cancer according to reproductive factors
Variable No of cases/No in subcohort Rate ratio (95% CI)
Parity:
Nulliparous 85/425 1.00
Parous 71/816 0.45 (0.32 to 0.63)
No of births:
1 44/388 0.55 (0.38 to 0.82)
2 22/323 0.36 (0.22 to 0.60)
≥3 5/105 0.28 (0.11 to 0.71)
Per additional birth among parous
women
— 0.68 (0.47 to 0.99)
Maternal age at birth of first child
(years):
<25 23/246 0.51 (0.31 to 0.83)
25-29 22/236 0.51 (0.31 to 0.84)
≥30 27/334 0.41 (0.26 to 0.65)
Per 5 years older among parous
women
— 0.95 (0.77 to 1.16)
Maternal age at birth of last child
(years):
<30 36/270 0.69 (0.45 to 1.04)
30-35 23/324 0.38 (0.23 to 0.63)
≥35 13/220 0.32 (0.17 to 0.58)
Per 5 years older among parous
women
0.89 (0.73 to 1.09)
All analyses stratified according to calendar year (in categories) and age at start of follow-up (in categories)
All rate ratios (except parity) adjusted for parity (nulliparous/parous) and number of additional births (linear)
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According to the sampling strategy we used the
unweighted case-cohort approach
3233 to estimate rate
ratios for ovarian cancer in a Cox proportional hazard
regression model, stratified according to the sampling
strata (age and year of enrolment). We used age as the
time scale to ensure that the estimates were based on
comparisons of women of the same age. The analysis
wascorrectedfordelayedentry,suchthatwomenwere
considered at risk only from the age at first date
infertility was evaluated. We estimated rate ratios as
previously suggested,
31 whereby all the women in the
subcohort contributed to all the relevant risk sets until
theendofthefollow-upperiodasaresultofdiagnosisof
c a n c e r ,d e a t h ,m i g r a t i o n ,o rc e n s o r i n g ,w h e r e a s
women outside the subcohort who were cases entered
only their own risk set. The 95% confidence intervals
were based on robust estimates of the variance-
covariance matrix of the Cox regression variables.
We evaluated the effects on overall risk of ovarian
cancer and risks for different histological subtypes
accordingtouseofthefollowingfertilitydrugs:follicle
stimulating hormone, human menopausal gonadotro-
phins, clomifene, human chorionic gonadotrophins,
and gonadotrophin releasing hormone, measured as
any use, number of cycles of use, and years since first
use. In the analyses, however, we pooled the two
gonadotrophins, follicle stimulating hormone and
human menopausal gonadotrophins, into one group
calledgonadotrophins,astheyhaveidenticalmodesof
action.Thewomeninthecohortwerealsotreatedwith
a large number of other types of fertility drug, such as
progesterone, estradiol, and diethylstilbestrol. We did
not, however, analyse the effects of these heteroge-
neous fertility drugs as each was given to only a few
women.
The 156 epithelial ovarian tumours included in the
analyses were classified into five histological types on
the basis of international classification of diseases for
oncology codes from the Danish Cancer Register, and
the Danish Registry of Pathology international classi-
fication of diseases (seventh revision): serous (n=90),
mucinous (n=12), endometrioid (n=23), clear cell
(n=8), and other types of epithelial ovarian cancer
(n=23). Potential confounding factors investigated in
the main analyses included parity (nulliparous or
parous), number of additional births, maternal age at
birthoffirstchild,andmaternalageatbirthoflastchild.
We entered all variables as time dependent covari-
ables, which changed values at the ages at which new
events occurred (for example, birth or start of new
treatment cycle). Information on the causes of inferti-
lityandanyuseoforalcontraceptiveswasnotavailable
formostwomenandwerethereforenotincludedinthe
main analyses but were analysed for the subset of
women for whom this information was available.
Statistical analyses were carried out with SAS/STAT
version 8.2.
RESULTS
The distribution of period of entry into the study and
age at entry for the 54362 women in the cohort has
beendescribedpreviously.
28Themedianyearforentry
was1989,themedianageatfirstevaluationofinfertility
was 30 years, and the median age at the end of follow-
up was 47 years. The women were followed up for a
median of 16.0 years (range 0.0-42.6 years), with 25%
followed for more than 23 years. The 54362 women
contributed 957454 person years of observation. The
median time from entry into the cohort and diagnosis
of cancer was 14.5 years (range 0.02-34.2 years), and
the age of the women at the time of diagnosis ranged
from 25 to 68 years (median 46 years). Fertility drugs
were used by 77 of the 156 (49%) women with ovarian
cancerand615ofthe 1241(50%)subcohortmembers.
Clomifenewasthemostcommonlyusedfertilitydrug,
taken by 58 cases (37%) and 415 subcohort members
(33%), followed by human chorionic gonadotrophins
(31% and 33%), gonadotrophins (17% and 15%), and
gonadotrophin releasing hormone (10% and 9%).
Table 2 |Rate ratios for ovarian cancer according to use of fertility drugs
Variables
No with ovarian cancer/No in subcohort Adjusted rate ratio (95% CI)
Gonadotrophins* Clomifene citrate hCG GnRH Gonadotrophins* Clomifene citrate hCG GnRH
Use:
Never 130/1057 98/824 107/828 141/
1131
1.00 1.00 1.00 1.00
Ever 26/184 58/417 49/413 15/110 0.83 (0.50 to 1.37) 1.14 (0.79 to 1.64) 0.89 (0.62 to 1.29) 0.80 (0.42 to 1.51)
No of cycles:
1-4 18/130 35/226 31/232 14/100 0.74 (0.41 to 1.33) 1.27 (0.83 to 1.94) 0.96 (0.62 to 1.48) 0.81 (0.42 to 1.56)
5-9 7/46 15/117 13/121 1/10 1.09 (0.49 to 2.44) 1.03 (0.57 to 1.86) 0.86 (0.47 to 1.57) 0.68 (0.09 to 5.38)
≥10 1/8 8/74 5/60 0/0 0.96(0.09to10.30) 0.92 (0.42 to 2.02) 0.70 (0.28 to 1.80) —
Timesincefirstuse(years):
<5 8/3 8/3 9/3 5/1 0.67 (0.29 to 1.54) 0.80 (0.32 to 1.99) 0.78 (0.35 to 1.75) 0.72 (0.28 to 1.89)
5-9 12/33 17/14 16/26 8/32 1.12 (0.58 to 2.21) 1.48 (0.80 to 2.73) 1.22 (0.67 to 2.23) 0.99 (0.43 to 2.33)
10-14 5/77 13/77 10/81 2/57 0.80 (0.29 to 2.18) 0.99 (0.53 to 1.87) 0.83 (0.43 to 1.62) 0.60 (0.13 to 2.70)
≥15 1/71 20/323 14/303 0/20 0.44 (0.06 to 3.14) 1.18 (0.70 to 1.99) 0.78 (0.43 to 1.42) —
All analyses stratified according to calendar year (in categories) and age at start of follow-up (in categories). Rate ratios adjusted for parity (nulliparous or parous) and number of additional
births (linear). hCG=human chorionic gonadotrophin; GnRH=gonadotrophin releasing hormone.
*Follicle stimulating hormone and human menopausal gonadotrophins.
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significantlyaffecttheoverallriskofovariancancer.In
contrast, parous women had a notably lower risk than
nulliparous women (rate ratio 0.45, 95% confidence
interval0.32to0.63),whichdecreasedwithnumberof
births (rate ratio 0.68, 0.47 to 0.99; table 1). Further-
more,theoverallriskofovariancanceramongwomen
inthecohortwasnotsignificantlyaffectedbyeitheruse
oforalcontraceptives(comparedwitheveruse,therate
ratio for never use 0.46, 0.20 to 1.05) or causes of
infertility (compared with anovulation, the rate ratio
for tubal disease was 1.47, 0.80 to 2.68, for endo-
metriosis was 0.92, 0.26 to 3.31, for uterine disorder
was0.65,0.14to2.93,andformalefactorwas0.57,0.27
to 1.24).
Afteradjustmentforparityandnumberofadditional
births, the overall risk of ovarian cancer was not
significantly affected by use of any fertility drug (rate
ratio 1.03, 0.73 to 1.47; data not shown), gonadotro-
phins(0.83,0.50to1.37),clomifene(1.14,0.79to1.64),
human chorionic gonadotrophins (0.89, 0.62 to 1.29),
or gonadotrophin releasing hormone (0.80, 0.42 to
1.51;table 2).Forallgroupsoffertilitydrugstheriskof
ovarian cancer was not substantially different accord-
ing to number of cycles of use or years since first use
(table 2). For all four types of fertility drug, the overall
risk of ovarian cancer was not noticeably affected by
parity, and none of the interaction terms were
statistically significant (table 3).
As a substantial proportion of the women in the
cohort had usedmore than one type of infertility drug,
the main effect of each type of drug was assessed. The
general results were not changed when the risk of
ovarian cancer was assessed only in those women who
hadusedonetypeoffertilitydrugcomparedwithnever
users (data not shown). When the rate ratios for the
most prevalent combinations of fertility drugs were
calculated, none of the five most commonly used
combinationssignificantlyaffectedrisk:clomifeneplus
humanchorionicgonadotrophins(rateratio1.13,95%
confidence interval 0.71 to 1.80), clomifene plus
gonadotrophins plus human chorionic gonadotro-
phins (0.60, 0.25 to 1.42), gonadotrophins plus
human chorionic gonadotrophins plus gonadotrophin
releasing hormone (1.02, 0.34 to 3.03), clomifene plus
gonadotrophins plus human chorionic gonadotro-
phins plus gonadotrophin releasing hormone (0.98,
0.44to2.18),andclomifeneplusgonadotrophins(2.20,
0.49 to 9.86).
Table 4 presents the risks of different histological
typesof ovariancancer. Of the 156 epithelialtumours,
serous tumours constituted the majority (58%), fol-
lowed by endometrioid tumours (15%), other tumours
(15%), mucinous tumours (8%), and clear cell tumours
(5%). The risk of serous cancers was significantly
increasedafteruseofclomifene(1.67,1.07to2.61).The
increase in risk was found mainly among women
followedfor15yearsormoreafterfirstuseofclomifene
when compared with never use (<5 years 1.22, 0.45 to
3.34;5-9years1.76,0.87to3.59,10-14years1.23,0.58
to2.59,≥15years2.17,1.15to4.08).Theriskofserous
cancer was not, however, related to the number of
cycles using clomifene, and the risk did not differ
according to parity (data not shown). A significantly
decreased risk for other types of ovarian cancers was
observedafteruseofhumanchorionicgonadotrophins
(0.24, 0.08 to 0.79), whereas the risks for mucinous,
endometrioid, and clear cell tumours were not
significantly affected by use of any of the four groups
of fertility drug.
Toallowaminimumlatencyperiodbetweenfirstuse
of fertility drugs and development of ovarian cancer,
thefewwomenwithadiagnosisofovariancancer(n=2)
within one year after first use of fertility drugs were
excludedfromtheanalyses.Virtuallynochangesinthe
risk estimates were observed (data not shown),
Table 3 |Rate ratios for ovarian cancer in nulliparous and parous women according to use of fertility drugs
Fertility drug and use
Nulliparous women Parous women
Interaction
(P value)
No with ovarian
cancer/No in
subcohort Rate ratio (95% CI)
No with ovarian
cancer/No in
subcohort Rate ratio (95% CI)
Gonadotrophins*:
Never 68/351 1.00 62/706 1.00
Ever 17/74 0.85 (0.44 to 1.64) 9/110 0.89 (0.43 to 1.83) 0.93
Clomifene citrate:
Never 50/276 1.00 48/548 1.00
Ever 35/149 1.28 (0.79 to 2.07) 23/268 1.04 (0.61 to 1.78) 0.56
hCG:
Never 57/285 1.00 50/543 1.00
Ever 28/140 0.95 (0.57 to 1.58) 21/273 0.87 (0.51 to 1.49) 0.81
GnRH:
Never 75/369 1.00 66/762 1.00
Ever 10/56 0.71 (0.32 to 1.54) 5/54 1.09 (0.41 to 2.91) 0.48
All analyses stratified according to calendar year (in categories) and age at start of follow-up (in categories). Rate ratios adjusted for parity (nulliparous
or parous) and number of additional births (linear). hCG=human chorionic gonadotrophins; GnRH=gonadotrophin releasing hormone.
*Follicle stimulating hormone and human menopausal gonadotrophins.
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biasedbyapotentialfertilitydruginducedacceleration
of the growth of an existent ovarian tumour.
Finally, to evaluate the effects of various causes of
infertility (anovulation, tubal disease, endometriosis,
uterine disorder, cervical disorder, and male factor)
and any use of oral contraceptives as potential
confounders, all the analyses were adjusted for these
two variables in the subsets of women for whom
information was available: causes of infertility, 45% of
cases and 51% of subcohort members, and any use of
oralcontraceptives,33%ofcasesand55%ofsubcohort
members. None of the risk estimates changed notice-
ably after adjustment for these potential confounders
(data not shown).
DISCUSSION
We found no convincing association between use of
fertility drugs and the overall risk of ovarian cancer.
Risk did not differ according to any use of fertility
drugs, number of cycles of use, length of follow-up
since first use of drug, or parity. Furthermore, none of
the risk estimates was noticeably changed after
adjustment for causes of infertility and any use of oral
contraceptivesinthesubsetsforwhichthisinformation
was available. When we analysed differences in risk
according to histological subtype, however, a 67%
increased risk for serous ovarian cancer after use of
clomifene was found, primarily among women fol-
lowed for 15 or more years.
Strengths and limitations
One of the most important strengths of the present
study in comparison with earlier cohort studies is the
precision of the risk estimates because of the large
number (n=156) of women with ovarian cancer
studied; in most previous cohort studies, the number
ofwomenrangedfromoneto12.
478121316-18Morecases
(n=45) were included in another study,
19 although that
study consisted of a mixture of non-epithelial, epithe-
lial, and borderline ovarian tumours. Thus all the
earlier cohort studies were limited by imprecise risk
estimates, especially in subgroups of fertility drug
users. Furthermore, only two cohort studies
419 had a
suitable reference group—that is, a control group of
infertile women who had not taken fertility drugs. The
others used standardised incidence ratios to compare
theriskofovariancancerincohortsofinfertilewomen
with that of the general population. This comparison
controls for the potential confounders of age and
calendar time but not for parity, causes of infertility,
and oral contraceptive use.
We showed previously that the infertile women in
this cohort are at a higher risk of ovarian cancer than
women in the general Danish population, even after
adjustment for parity.
27 The case-cohort technique
used in the present study, however, showed no strong
association between use of fertility drugs and risk of
ovarian cancer in the cohort. Our data therefore
suggestthatfactorsrelatedtothediagnosisofinfertility
(for example, genetic or biological), and not the use of
fertility drugs, increase the overall risk of ovarian
cancer.Onestrengthofourstudyisthevirtualabsence
of losses to follow-up, as a result of the precise linkage
between our cohort and the Danish population based
registers and complete ascertainment of diagnoses for
ovariancancer.Furthermore,wehaddetailedinforma-
tion on the various types of fertility drugs used, which
allowed examination of their potentially different
effects. Few of the previous cohort studies
48121319and
case-control studies
61020were able to assess the effects
of different types of fertility drugs.
Table 4 |Rate ratios for histological subgroups of ovarian cancer according to use of fertility drugs
Fertility drugs
and use
No with ovarian cancer/No in subcohort Adjusted rate ratio (95% CI)
Serous Mucinous Endometrioid Clear cell Other Serous Mucinous Endometrioid Clear cell Other
Gonadotrophins*:
Never 72/1057 9/1057 21/1057 6/1057 22/1057 1.00 1.00 1.00 1.00 1.00
Ever 18/184 3/184 2/184 2/184 1/184 1.04
(0.57 to 1.90)
1.14
(0.33 to 3.99)
0.74
(0.19 to 2.93)
1.59
(0.34 to 7.55)
0.57
(0.14 to 2.28)
Clomifene citrate:
Never 48/824 9/824 19/824 4/824 18/824 1.00 1.00 1.00 1.00 1.00
Ever 42/417 3/417 4/417 4/417 5/417 1.67
(1.07 to 2.61)
0.60
(0.18 to 2.08)
0.68
(0.27 to 1.67)
1.62
(0.55 to 4.74)
0.70
(0.29 to 1.73)
hCG:
Never 54/828 8/828 18/828 6/828 21/828 1.00 1.00 1.00 1.00 1.00
Ever 36/413 4/413 5/413 2/413 2/413 1.29
(0.83 to 2.01)
0.61
(0.20 to 1.79)
0.68
(0.28 to 1.67)
0.44
(0.10 to 1.92)
0.24
(0.08 to 0.79)
GnRH:
Never 80/1131 11/1131 22/1131 6/1131 22/1131 1.00 1.00 1.00 1.00 1.00
Ever 10/110 1/110 1/110 2/110 1/110 0.93
(0.44 to 1.98)
1.47
(0.26 to 8.21)
0.75
(0.13 to 4.38)
2.89
(0.54 to 15.54)
1.14
(0.27 to 4.85)
All analyses stratified according to calendar year (in categories) and age at start of follow-up (in categories). Rate ratios adjusted for parity (nulliparous and parous) and number of additional
births (linear). hCG=human chorionic gonadotrophins; GnRH=gonadotrophin releasing hormone.
*Follicle stimulating hormone and human menopausal gonadotrophins.
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had a relatively long follow-up period, the median age
at the end of follow-up (47 years) was below the usual
peak age (early 60s) for ovarian cancer, which might
have weakened our estimates. Potentially important
riskfactorssuchasthecauseofinfertilityanduseoforal
contraceptives were registered for only a few of the
women and could therefore be analysed only for the
subsetsthatincludedthisinformation.Inlinewithmost
previousstudies,
13151920however,ourresultsshowthat
adjustment for oral contraceptive use and causes of
infertilitydoesnotchangetheriskestimatesmarkedly.
Furthermore, we found no association between oral
contraceptive use and use of fertility drugs or between
causes of infertility and use of fertility drugs (data not
shown), which thus add further weight that our results
arenotanartefactduetouncontrolledconfoundingby
these factors. However, as several studies have shown
that certain causes of infertility might be linked
independently to ovarian cancer,
4-1523-2634 both our
resultsandthoseofpreviousstudiesmightpartlyreflect
methodological differences and weaknesses in assess-
ment of the causes of infertility. For example,
researchers may not have complete knowledge of the
extent to which a woman has been evaluated for all
causes of infertility. Clearly this topic needs further
assessment in future studies.
Comparisons with the literature
Two theories are usually used to explain how fertility
drugs might affect the risk of ovarian cancer. The
incessant ovulation theory suggests that repeated,
uninterrupted ovulation causes microtrauma to the
ovarian epithelium, leading to malignant
transformations.
35 The gonadotrophin theory suggests
that exposure of the ovaries to endogenous or
exogenous gonadotrophins is directly carcinogenic.
36
Even though these theories are biologically plausible,
only two epidemiological studies,
45done in the early
1990s, found a notable association between use of
fertility drugs and the risk of invasive ovarian cancer.
The main finding in one retrospective cohort study
4
wasarelativeriskof11.1(95%confidenceinterval1.50
to 82.3) among infertile women with long term
exposure to clomifene (≥12 cycles); however, the
results of this study are difficult to interpret because
of the small number of cases and the limited informa-
tion on confounding factors. The other study that has
undergone close scrutiny is the collaborative analysis
of12case-controlstudiesintheUnitedStates.
5Therisk
of ovarian cancer was dramatically increased among
nulligravid women who used fertility drugs (rate ratio
27, 95% confidence interval 2.30 to 315.60), but
interpretation of the results is difficult as information
on use of specific types of fertility drug was not
available. In the US study
5 the indication of a causal
relation between fertility drugs and ovarian cancer is
also hampered by a low statistical precision of the risk
estimate (wide confidence intervals) because only a
limited number of controls had used fertility drugs.
Furthermore, the validity of the study has also been
questioned by others owing to the possible role of
several potential biases, including diagnostic bias,
selection bias, and recall bias.
37
Our results contrast with those of the two epidemio-
logical studies
45 but are in line with those of most
subsequent epidemiological studies
7-21 and are gener-
allyreassuring,aswefoundnodifferenceinoverallrisk
of ovarian cancer according to any use of the four
groupsoffertilitydrugstudied,numberofcyclesofuse,
length of follow-up since first use, and parity. The
absence of a dose-response relation between the
number of cycles and the risk of ovarian cancer found
in our study is in line with most previous
findings,
81117-20 but not all.
4 Only one study
19 also
examined the association between the risk of ovarian
cancer and follow-up since first use of fertility drugs,
and, as with our study, found no convincing associa-
tion. Both our results and those of that study
19 are,
however, limited as only a small proportion of the
women in the cohorts were followed up for a sufficient
time. Longer follow-up is needed to assess the effect of
latency on risk of ovarian cancer after exposure to
fertility drugs.
The collaborative analysis of 12 case-control studies
in the United States
5 suggested that infertile women
who received fertility drugs but remained nulliparous
may be at particularly high risk. This result is in line
with those of two subsequent studies that found
statistically non-significantly increased risks among
women who remained nulliparous.
1519 However, our
study, in line with others,
101420 found no association
between overall risk of ovarian cancer and use of
fertility drugs after stratifying for parity. Further
investigations on this topic are warranted.
The detailed histological information contained in
theDanishCancerRegistryandtheDanishRegistryof
Pathology, in combination with the large number of
cases of ovarian cancer in our cohort, enabled us to
analyse potential differences in risk according to
histological subtype. In contrast to the analyses of
overall risk of ovarian cancer, we found a significant
67% increase in risk of serous tumours after use of
clomifene,primarilywhenfollow-upwasformorethan
15 years since first use. The risks for mucinous,
endometrioid, and clear cell tumours were not
significantly affected by use of any of the four types of
fertilitydrugs.Nopreviouscohortstudyhasaddressed
the association between infertility and risk of ovarian
cancer according to histological type. In a pooled
analysisofcase-controlstudies,however,researchers
15
found no associationbetween use of fertility drugsand
the risks for the different histological subtypes of
epithelial ovarian tumours. Several studies have
suggested that mucinous tumours are less affected by
hormonal (oral contraceptives) and parity related
factors than non-mucinous tumours.
38-44 It is therefore
plausiblethatthecarcinogeniceffectoffertilitydrugsis
less pronounced for mucinous tumours. However,
only the risk estimates for the association between use
offertilitydrugsandseroustumourscanbeconsidered
to be based on a sufficiently large number of cases to
RESEARCH
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althoughthe associationbetweenuse of clomifeneand
risk of serous tumours may be real and important, we
are not able to draw firm conclusions on the other
histologicaltypesofovariancancerasthelowprecision
oftheriskestimatesforotherhistologicalsubtypesthan
serous tumours makes it hard to determine whether
they do differ from the risk estimates for serous
tumours. Also, we cannot rule out the possibility that
the positive association between use of clomifene and
risk of serous tumours arose from multiple compar-
isons.Furtherlongtermfollow-upstudiesaretherefore
needed to confirm our findings.
Conclusions
The results of our large, nationwide study, which
represents the largest number of cases of ovarian
cancer in any cohort of women with infertility
problems to date, generally concur with those of most
previous epidemiological studies and provide reassur-
ing evidence for the absence of a strong association
betweenuseoffertilitydrugsandriskofovariancancer.
However,asmanyofthewomeninourcohorthavenot
yet reached the usual peak age for ovarian cancer, we
will continue to monitor the risk to try to establish a
moredefinitelinkbetweenuseoffertilitydrugsandrisk
of ovarian cancer. In a society where infertility in
women and maternal age at birth of the first child are
increasing, the unfavourable effects of fertility drugs
(forexample,apossiblesmallincreaseinriskofovarian
cancer) should be balanced against the physical and
psychological benefits of a pregnancy made possible
only by the use of these drugs.
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